AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
View PDF
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Hepatitis C Virus Core Protein Increases Expression of DR4 and DR5 in Peripheral Blood Mononuclear Cells

Janelle Guy2( )Lechi Nwanegwo1Emmanuella Sobo1Kadir Aslan2( )
Department of Biology, Morgan State University, USA
Department of Civil Engineering, Morgan State University, 1700 East Cold Spring Lane, Baltimore, MD 21251 USA
Show Author Information

Abstract

A robust innate and adaptive immune response is essential to viral clearance. Hepatitis C virus (HCV) infection typically leads to alteration of the innate and adaptive immune response, which is caused by interaction of HCV core protein with various host factors. It is important to investigate the alterations to the immune response during the transition from acute HCV to chronic HCV infection to develop better therapeutic methods for HCV infection. In this work, to determine whether HCV viral persistence occurs via tumor necrosis apoptosis-inducing ligand (TRAIL)-mediated apoptosis, we stimulated peripheral blood mononuclear cells (PBMCs) with recombinant HCV core protein within 12 h to measure the relative expression of death receptors 4 and 5 (DR4 and DR5) in PBMCs. We show that recombinant HCV core protein causes increased DR4 and DR5 expression in PBMCs. We also show that TRAIL interacts with DR4 and DR5 after cleavage of membrane-bound TRAIL yielding soluble TRAIL. Our results show that HCV core protein increases PBMC susceptibility to apoptosis and may cause increased TRAIL pathway activity within 12 h of infection. In addition, we observed that increased death receptor expression may contribute to HCV pathogenesis, as typically observed in chronically HCV-infected individuals.

References

[1]

U.A. Ashfaq, T. Javed, S. Rehman, et al., An overview of HCV molecular biology, replication and immune responses. Virology Journal, 2011, 8(1): 161.

[2]

A.A. Mohamed, T.A. Elbedewy, M. El-Serafy, et al., Hepatitis C virus: A global view. World Journal of Hepatology, 2015, 7(26): 2676.

[3]

N. Pavio, M.M. Lai, The hepatitis C virus persistence: how to evade the immune system? Journal of Biosciences, 2003, 28(3): 287-304.

[4]

M. Irshad, An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World Journal of Gastroenterology, 2013, 19(44): 7896.

[5]

C. Kao, G. Yi, and H.C. Huang, The core of hepatitis C virus pathogenesis. Current Opinion in Virology, 2016, 17: 66-73.

[6]

A. Ulsenheimer, J.T. Gerlach, M. -C. Jung, et al., Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology, 2005, 41(3): 643-651.

[7]

L. Highleyman, HIV/HCV coinfection: a new era of treatment. BETA: Bulletin of Experimental Treatments for AIDS: A Publication of the San Francisco AIDS Foundation 2010, 23(4): 30-47.

[8]

R. D'souza, G.R. Foster, Diagnosis and treatment of hepatitis C. Journal of the Royal Society of Medicine, 2004, 97(5): 223-225.

[9]

A. Kohli, A. Shaffer, A. Sherman, et al., Treatment of hepatitis C: A systematic review. Jama, 2014, 312(6): 631-640.

[10]

H.C. Li, S.Y. Lo, Hepatitis C virus: Virology, diagnosis and treatment. World Journal of Hepatology, 2015, 7(10): 1377.

[11]

S. Elmore, Apoptosis: A review of programmed cell death. Toxicologic Pathology, 2007, 35(4): 495-516.

[12]

S. Fulda, K.M. Debatin, Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 2006, 25(34): 4798-811.

[13]

T. Zhou, J.D. Mountz, and R.P. Kimberly, Immunobiology of tumor necrosis factor receptor superfamily. Immunologic Research, 2002, 26(1-3): 323-336.

[14]

A. Glässner, M. Eisenhardt, B. Krämer, et al., NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Laboratory Investigation, 2012, 92(7): 967-977.

[15]

D. Peppa, U.S. Gill, G. Reynolds, et al., Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. The Journal of Experimental Medicine, 2013, 210(1): 99-114.

[16]

G. Stary, I. Klein, S. Kohlhofer, et al., Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood, 2009, 114(18): 3854-3863.

[17]

D. Trabzuni, K.S. Famulski, M. Ahmad, Functional analysis of tumour necrosis factor-α-related apoptosis-inducing ligand (TRAIL): Cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochemical Journal, 2000, 350(2): 505-510.

[18]

V. Falcón, N. Acosta-Rivero, M. Shibayama, et al., Evidences of apoptosis in hepatitis C virus-infected hepatocytes and peripheral blood monocuclear cells in the absence of liver injury. Am J Inf Dis, 2005, 1: 43-49.

Nano Biomedicine and Engineering
Pages 186-198
Cite this article:
Guy J, Nwanegwo L, Sobo E, et al. Hepatitis C Virus Core Protein Increases Expression of DR4 and DR5 in Peripheral Blood Mononuclear Cells. Nano Biomedicine and Engineering, 2018, 10(2): 186-198. https://doi.org/10.5101/nbe.v10i2.p186-198

394

Views

28

Downloads

0

Crossref

0

Scopus

Altmetrics

Received: 03 May 2018
Accepted: 04 June 2018
Published: 29 June 2018
© Janelle Guy, Lechi Nwanegwo, Emmanuella Sobo, and Kadir Aslan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Return